Amicus Therapeutics, Inc. (0HF9.L)
USD 9.86
(-1.0%)
USD 9.86
(-1.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 445.05 Million USD | -1.56% |
| 2022 | 452.12 Million USD | 2.72% |
| 2021 | 440.12 Million USD | -0.36% |
| 2020 | 441.73 Million USD | 110.12% |
| 2019 | 210.22 Million USD | -34.66% |
| 2018 | 321.74 Million USD | 95.62% |
| 2017 | 164.47 Million USD | 6.48% |
| 2016 | 154.46 Million USD | 271.3% |
| 2015 | 41.6 Million USD | 189.9% |
| 2014 | 14.35 Million USD | -0.85% |
| 2013 | 14.47 Million USD | 1976.47% |
| 2012 | 697 Thousand USD | -33.24% |
| 2011 | 1.04 Million USD | -55.33% |
| 2010 | 2.33 Million USD | -40.11% |
| 2009 | 3.9 Million USD | 226.8% |
| 2008 | 1.19 Million USD | -56.12% |
| 2007 | 2.72 Million USD | -23.64% |
| 2006 | 3.56 Million USD | 251.56% |
| 2005 | 1.01 Million USD | 0.0% |
| 2003 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 444.05 Million USD | -0.1% |
| 2024 Q1 | 444.49 Million USD | -0.13% |
| 2023 Q1 | 452.01 Million USD | -0.02% |
| 2023 Q2 | 452.16 Million USD | 0.03% |
| 2023 Q3 | 454.29 Million USD | 0.47% |
| 2023 Q4 | 445.05 Million USD | -2.03% |
| 2023 FY | 445.05 Million USD | -1.56% |
| 2022 Q4 | 452.12 Million USD | 0.28% |
| 2022 Q2 | 451.03 Million USD | 0.74% |
| 2022 Q3 | 450.86 Million USD | -0.04% |
| 2022 Q1 | 447.7 Million USD | 1.72% |
| 2022 FY | 452.12 Million USD | 2.72% |
| 2021 Q3 | 439.38 Million USD | -0.53% |
| 2021 FY | 440.12 Million USD | -0.36% |
| 2021 Q2 | 441.74 Million USD | 0.17% |
| 2021 Q4 | 440.12 Million USD | 0.17% |
| 2021 Q1 | 440.98 Million USD | -0.17% |
| 2020 FY | 441.73 Million USD | 110.12% |
| 2020 Q1 | 209.76 Million USD | -0.22% |
| 2020 Q2 | 202.21 Million USD | -3.6% |
| 2020 Q3 | 440.57 Million USD | 117.87% |
| 2020 Q4 | 441.73 Million USD | 0.26% |
| 2019 Q3 | 205.3 Million USD | 9.2% |
| 2019 Q1 | 207.44 Million USD | -35.53% |
| 2019 FY | 210.22 Million USD | -34.66% |
| 2019 Q2 | 188 Million USD | -9.37% |
| 2019 Q4 | 210.22 Million USD | 2.4% |
| 2018 Q4 | 321.74 Million USD | 0.92% |
| 2018 Q3 | 318.8 Million USD | 88.15% |
| 2018 Q2 | 169.44 Million USD | 1.6% |
| 2018 Q1 | 166.76 Million USD | 1.39% |
| 2018 FY | 321.74 Million USD | 95.62% |
| 2017 Q1 | 156.85 Million USD | 1.36% |
| 2017 FY | 164.47 Million USD | 6.48% |
| 2017 Q4 | 164.47 Million USD | 1.76% |
| 2017 Q3 | 161.63 Million USD | 1.55% |
| 2017 Q2 | 159.17 Million USD | 1.47% |
| 2016 Q1 | 38.5 Million USD | -7.43% |
| 2016 Q3 | 66.02 Million USD | 1.12% |
| 2016 Q4 | 154.74 Million USD | 134.38% |
| 2016 FY | 154.46 Million USD | 271.3% |
| 2016 Q2 | 65.29 Million USD | 69.56% |
| 2015 Q1 | 14.39 Million USD | 0.33% |
| 2015 Q4 | 41.6 Million USD | -16.8% |
| 2015 Q3 | 50 Million USD | 0.0% |
| 2015 FY | 41.6 Million USD | 189.9% |
| 2015 Q2 | - USD | -100.0% |
| 2014 Q3 | 14.3 Million USD | -0.38% |
| 2014 Q4 | 14.35 Million USD | 0.34% |
| 2014 Q2 | 14.35 Million USD | -0.4% |
| 2014 FY | 14.35 Million USD | -0.85% |
| 2014 Q1 | 14.41 Million USD | -0.4% |
| 2013 Q3 | 398 Thousand USD | -20.08% |
| 2013 Q4 | 14.47 Million USD | 3536.43% |
| 2013 Q1 | 597 Thousand USD | -14.35% |
| 2013 Q2 | 498 Thousand USD | -16.58% |
| 2013 FY | 14.47 Million USD | 1976.47% |
| 2012 Q3 | 900 Thousand USD | -31.51% |
| 2012 Q2 | 1.31 Million USD | -23.87% |
| 2012 FY | 697 Thousand USD | -33.24% |
| 2012 Q1 | 1.72 Million USD | 65.33% |
| 2012 Q4 | 697 Thousand USD | -22.56% |
| 2011 Q2 | 1.67 Million USD | -15.78% |
| 2011 FY | 1.04 Million USD | -55.33% |
| 2011 Q4 | 1.04 Million USD | -23.07% |
| 2011 Q3 | 1.35 Million USD | -18.79% |
| 2011 Q1 | 1.98 Million USD | -15.1% |
| 2010 Q4 | 2.33 Million USD | -13.32% |
| 2010 FY | 2.33 Million USD | -40.11% |
| 2010 Q2 | 3.06 Million USD | -12.1% |
| 2010 Q3 | 2.69 Million USD | -12.04% |
| 2010 Q1 | 3.48 Million USD | -10.64% |
| 2009 FY | 3.9 Million USD | 226.8% |
| 2009 Q4 | 3.9 Million USD | -7.99% |
| 2009 Q3 | 4.24 Million USD | 53.99% |
| 2009 Q2 | 2.75 Million USD | 200.0% |
| 2009 Q1 | 918 Thousand USD | -23.12% |
| 2008 Q3 | 1.57 Million USD | -19.46% |
| 2008 Q1 | 2.33 Million USD | -14.08% |
| 2008 Q4 | 1.19 Million USD | -24.09% |
| 2008 Q2 | 1.95 Million USD | -16.47% |
| 2008 FY | 1.19 Million USD | -56.12% |
| 2007 FY | 2.72 Million USD | -23.64% |
| 2007 Q3 | 3.09 Million USD | -10.5% |
| 2007 Q2 | 3.45 Million USD | 6.4% |
| 2007 Q1 | 3.24 Million USD | -8.83% |
| 2007 Q4 | 2.72 Million USD | -12.06% |
| 2006 FY | 3.56 Million USD | 251.56% |
| 2006 Q4 | 3.56 Million USD | 0.0% |
| 2005 FY | 1.01 Million USD | 0.0% |
| 2005 Q4 | 1.01 Million USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Dynavax Technologies Corporation | 256.91 Million USD | -73.233% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 95.342% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -971.734% |
| Perrigo Company plc | 4.07 Billion USD | 89.074% |
| Illumina, Inc. | 2.26 Billion USD | 80.325% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 98.725% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -44405.9% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 96.873% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -156.145% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -1548.977% |
| Waters Corporation | 2.35 Billion USD | 81.106% |
| Biogen Inc. | 7.33 Billion USD | 93.935% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -1068.011% |
| Evolus, Inc. | 126.54 Million USD | -251.697% |
| Adicet Bio, Inc. | 17.7 Million USD | -2414.032% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 17.726% |
| FibroGen, Inc. | 170.45 Million USD | -161.101% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 83.727% |
| Homology Medicines, Inc. | 44.05 Million USD | -910.258% |
| Geron Corporation | 85.89 Million USD | -418.119% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 81.441% |
| Editas Medicine, Inc. | 36.53 Million USD | -1118.138% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 83.534% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -931.017% |
| bluebird bio, Inc. | 330.32 Million USD | -34.733% |
| Myriad Genetics, Inc. | 145 Million USD | -206.937% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -2031.077% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 60.749% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -35222.143% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -285.847% |
| Zoetis Inc. | 6.8 Billion USD | 93.458% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -10010.382% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 79.469% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -669.04% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 44.946% |
| Nektar Therapeutics | 230.4 Million USD | -93.167% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | -138.801% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -14378.172% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -1125.282% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 69.381% |
| Verastem, Inc. | 41.55 Million USD | -970.96% |
| OPKO Health, Inc. | 326.56 Million USD | -36.285% |
| Exelixis, Inc. | 189.94 Million USD | -134.311% |
| Imunon, Inc. | 1.13 Million USD | -38964.49% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 68.137% |
| uniQure N.V. | 138.4 Million USD | -221.554% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | -3.889% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -294641.06% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 70.315% |
| Blueprint Medicines Corporation | 774.12 Million USD | 42.508% |
| Insmed Incorporated | 1.2 Billion USD | 63.035% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -680.97% |
| TG Therapeutics, Inc. | 110.79 Million USD | -301.696% |
| Incyte Corporation | 38.28 Million USD | -1062.429% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 49.281% |